How Is Lean Mass Preservation Measured?
Lean mass preservation is assessed in research settings using body-composition endpoints such as dual-energy X-ray absorptiometry (DXA), bioelectrical impedance analysis (BIA), and magnetic resonance imaging (MRI), along
What is lean mass preservation and how is it measured?
Lean mass preservation refers to the maintenance or minimisation of loss of fat-free mass (FFM) during interventions that induce weight loss, such as GLP-1 receptor agonist therapy. In research settings, it is measured using body-composition techniques that partition body mass into fat mass and lean (fat-free) compartments. The most commonly referenced methods include dual-energy X-ray absorptiometry (DXA), bioelectrical impedance analysis (BIA), and magnetic resonance imaging (MRI). These techniques provide quantitative estimates of lean tissue, typically reported in kilograms or as a percentage of total body mass. No single molecular formula or sequence defines lean mass preservation; it is a physiological outcome rather than a discrete compound.
The measurement of lean mass preservation is central to trials investigating next-generation obesity pharmacotherapies, particularly those combining GLP-1 receptor agonists with agents targeting muscle-preserving pathways. The receptor families most frequently implicated in this context include the GLP-1 receptor and signalling pathways involved in muscle protein synthesis and degradation, such as the activin type II receptor pathway.
Research Studies
Semaglutide and lean mass changes in obesity trials
Semaglutide, a GLP-1 receptor agonist, has been shown to achieve substantial weight loss in adults with obesity. However, clinical observations indicate that a proportion of the weight lost may include lean mass. In trials, lean mass preservation is assessed by comparing DXA-derived fat-free mass before and after treatment. The evidence notes that GLP-1-based therapies have limitations including weight loss plateaus and inter-individual variability, which has prompted investigation into adjunctive strategies to preserve lean mass [1].
Trevogrumab and garetosmab with semaglutide for lean mass preservation
A clinical trial (NCT06299098) is investigating trevogrumab, an anti-myostatin antibody, and garetosmab, an anti-activin A antibody, in combination with semaglutide in adults with obesity. The study is designed in three parts: Part A in healthy participants, and Parts B and C in participants with obesity. The primary aim includes assessing safety and efficacy of the combination for weight loss, fat loss, and lean mass preservation. Lean mass is a key endpoint, measured using body-composition assessments [2].
Multi-receptor agonists and body composition endpoints
Emerging multi-receptor agonists are being developed to address limitations of current GLP-1 receptor agonists. In research, these agents are evaluated for their effects on body weight and body composition, including lean mass. The evidence indicates that next-generation approaches are needed due to weight regain upon discontinuation of GLP-1 therapies. Measurement of lean mass preservation in these studies typically employs DXA or MRI to quantify fat-free mass [1].
DXA as a reference method for lean mass measurement
Dual-energy X-ray absorptiometry (DXA) is widely used in clinical trials to measure lean mass. It provides estimates of fat-free mass in specific regions (e.g., appendicular lean mass) and total body. In the context of obesity pharmacotherapy, DXA is used to determine whether interventions preserve lean mass during weight loss. The evidence does not specify a universal threshold for defining successful preservation; rather, changes are compared between treatment groups [1][2].
Bioelectrical impedance analysis (BIA) in lean mass assessment
Bioelectrical impedance analysis (BIA) is a non-invasive method that estimates body composition based on the conduction of electrical currents through tissues. It is less expensive and more portable than DXA or MRI, but its accuracy can be affected by hydration status and body fat distribution. In research settings, BIA is sometimes used as a secondary measure of lean mass, though DXA remains the preferred method in many trials [1].
Magnetic resonance imaging (MRI) for precise lean mass quantification
MRI offers high-resolution imaging of skeletal muscle and can differentiate lean tissue from fat. It is used in some studies to measure muscle volume and cross-sectional area, providing a more detailed assessment of lean mass preservation than DXA. However, MRI is costly and less feasible for large-scale trials. The evidence does not provide specific MRI protocols for lean mass preservation in obesity pharmacotherapy [1].
Functional and biochemical markers of lean mass preservation
Beyond imaging, lean mass preservation may be inferred from functional measures such as muscle strength (e.g., handgrip dynamometry) and physical performance tests. Biochemical markers, including myostatin and activin A, are also being explored as surrogates for muscle preservation. In the trevogrumab and garetosmab trial, these markers are likely assessed alongside body-composition endpoints [2].
Comparison of lean mass measurement methods
The table below summarises key characteristics of common methods used to measure lean mass preservation in research.
| Method | Principle | Common use | Limitations |
|---|---|---|---|
| DXA | X-ray attenuation | Reference method in trials | Radiation exposure, not portable |
| BIA | Electrical impedance | Field studies, secondary measure | Hydration-dependent, less accurate |
| MRI | Magnetic resonance | Detailed muscle quantification | Costly, limited availability |
No single method is universally accepted; the choice depends on study design, budget, and required precision [1][2].
Animal and in vitro models of lean mass preservation
Preclinical studies using animal models (e.g., mice, rats) and in vitro cell cultures are used to investigate mechanisms of muscle preservation. These models allow controlled manipulation of pathways such as myostatin inhibition. However, findings from animal or in vitro studies may not directly translate to humans. The evidence does not provide specific animal data on lean mass preservation in the context of GLP-1 receptor agonists [1].
If you are reading this for personal health reasons
The compounds and measurement methods described here are for laboratory research use only. We do not provide dosing, medical guidance, or recommendations for personal use. If you are considering any compound for yourself, consult a licensed clinician.
Sources
- [1] Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.
- [2] A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation.